Brief: Mabion Receives FDA Confirmation For Pre-IND Type B Meeting On MabionCD20 As Orphan Drug For ITP
26/08/2026 12:27
BRIEF-Mabion Receives FDA Confirmation For Pre-IND Type B Meeting On MabionCD20 As Orphan Drug For ITP Aug 26 (Reuters) - Mabion SA MABP.WA:
RECEIVES US FOOD AND DRUG ADMINISTRATION (FDA) CONFIRMATION FOR PRE-IND TYPE B MEETING ON OCT 5 REGARDING MABIONCD20 AS ORPHAN DRUG FOR IMMUNE THROMBOCYTOPENIA (ITP)
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects